Endostatin, an Inhibitor of Angiogenesis, Decreases After Bidirectional Superior Cavopulmonary Anastomosis

Aida Field-Ridley · Ritva Heljasvaara · Taina Pihlajaniemi · Ian Adatia · Christine Sun · Roberta L. Keller · Wen Hui Gong · Sanjeev Datar · Peter Oishi · Jeffrey R. Fineman

Abstract Pulmonary arteriovenous malformations (PAVMs) are a common source of morbidity after bidirectional superior cavopulmonary anastomosis (Glenn). The diversion of hepatic venous effluent away from the pulmonary circulation after Glenn appears to play a significant role in the pathogenesis of PAVMs. Although the liver is known to produce factors that regulate vascular development, specific hepatic inhibitors of angiogenesis have not been described in the post-Glenn population. Endostatin, produced from its precursor collagen XVIII, is a potent inhibitor of angiogenesis produced by the liver. This study aimed to investigate the hypothesis that endostatin levels decrease in patients after Glenn. Levels of endostatin and its precursor, long type-collagen XVIII, were determined by enzyme-linked immunoassay and immunoprecipitation, respectively, for serum samples from 38 patients undergoing Glenn, total cavopulmonary anastomosis (Fontan), or biventricular repair of cardiac defects. Samples were obtained before surgery and 24 h afterward. In patients undergoing a bidirectional Glenn procedure, endostatin levels decreased after surgery (n = 17; 4.42 vs 3.34 ng/ml; p < 0.001), and long type-collagen XVIII levels increased by 200% (n = 10; p = 0.0001). However, endostatin levels did not change after surgery in patients undergoing Fontan (n = 13) or biventricular repair (n = 8). In patients undergoing Fontan, long-type collagen XVIII increased by 18% (p < 0.01), whereas in control subjects, the levels were unchanged. These data suggest that the diversion of hepatic blood flow away from the pulmonary circulation in patients after the Glenn procedure inhibits endostatin production from collagen XVIII, resulting in decreased circulating serum endostatin levels. A decrease in endostatin may promote angiogenesis. The mechanism whereby the pulmonary circulation processes endostatin and its potential role in the pathogenesis of PAVMs warrant further study.

Keywords Angiogenesis inhibitor · Cardiac repair · Collagen XVIII · Congenital heart disease · Endostatin · Pulmonary arteriovenous malformations

Pulmonary arteriovenous malformations (PAVMs) that develop after superior cavopulmonary anastomosis or bidirectional Glenn surgery are an important cause of morbidity secondary to progressive cyanosis in the population with complex congenital heart disease [1]. The proportion of patients who experience PAVM ranges from 35 to 100%, depending on the mode and timing of detection [24].

The mechanism by which PAVMs arise is not understood. It has been recognized for the past 15 years that diversion of hepatic venous effluent away from the lung or impaired hepatic function plays a significant role in the
The pathogenesis of PAVMs [19]. Furthermore, structural similarities exist between PAVMs developing after bidirectional Glenn and the hepatopulmonary syndrome (HPS) from biliary and liver disease [7]. Specifically, there are dilated precapillary and capillary pulmonary blood vessels, increased microvessel density, and animal model data consistent with abnormal vascular remodeling [20, 23]. Alterations in pro-angiogenic factors [e.g., upregulation of vascular endothelial growth factor (VEGF) receptors and increased circulating VEGF levels] have been described in association with PAVMs in children who have undergone bidirectional Glenn [21, 22]. Although VEGF is a known circulating pro-angiogenic factor [5], the role of hepatic-specific regulators of angiogenesis and their exclusion from the pulmonary circulation in the development of PAVMs after bidirectional Glenn are unknown.

The liver participates in regulating angiogenesis [2]. Endostatin, a potent inhibitor of angiogenesis, is the 20-kDa protein from the C-terminus of collagen XVIII [14]. The long isoform of collagen XVIII is hepatocyte specific [13]. This study aimed to describe and compare changes in endostatin and its precursor collagen XVIII in patients who had undergone Glenn and total cavopulmonary anastomosis (Fontan) with those of patients who had complete biventricular repair of congenital heart disease.

Materials and Methods

From a prior institutional review board (IRB)-approved study, 38 plasma samples were obtained from patients undergoing bidirectional Glenn, modified Fontan operation, or biventricular repair (Table 1). Samples were obtained from a systemic artery before the respective surgical procedure and 24 h afterward.

Endostatin Analysis

We determined endostatin levels by enzyme-linked immunosassay (ELISA) (R & D Systems, Inc., Minneapolis, MN). The assessed interassay precision of the kit used demonstrated a coefficient of variation between 3.6 and 6.9 %. Intraassay precision demonstrated a coefficient of variation between 5.7 and 7.9 %. Plasma samples analyzed in this study were thawed from −80 °C to room temperature. Measurements were performed in duplicate at 1:50 and 1:100 dilutions. Measurement variability was minimal and comparable with that reported in the kit.

Collagen XVIII Analysis

Long-type collagen XVIII was determined by previously published methods [17]. Briefly, plasma samples were immunoprecipitated with the monoclonal anti-all type XVIII antibody, DB144-N2, bound to affinity-purified antimouse immunoglobulin G (IgG)-coated magnetic beads (Dynabeads M-280; Dynal, Oslo, Norway). The DB144-N2 antibody was incubated with antimouse IgG-coated beads in phosphate-buffered saline (PBS) buffer (pH 7.4) containing 0.1 % bovine serum albumin (BSA) for 2 h at room temperature.

After several washes in PBS, 100 µl of human plasma was incubated with the DB144-N2 antibody–coated beads overnight at 4 °C. Unbound proteins were removed by washing with PBS containing 1 % Triton-X100 and 0.1 % sodium dodecyl sulfate (SDS). Specifically, bound polypeptides were eluted by boiling for 3 min in SDS sample buffer containing 5 % 2-mercaptoethanol, resolved by 7–12 % SDS-polyacrylamide gel electrophoresis (PAGE), and detected by Western blot with anti-LONG variant antibody (QH 1415).

Western Blot Analysis

A 20-µl protein sample was loaded onto SDS-PAGE, electrotransferred to a polyvinylidene fluoride (PVDF) membrane (Immobilon; Millipore Billerica, MA), and probed with rabbit polyclonal antibodies against long-type collagen XVIII at a concentration of 1 µg/ml in 1 % fat-free milk powder followed by goat antirabbit antibody. After extensive washing of the membrane with 1 × PBS 0.1 % Tween, proteins reactive to QH 1415 were visualized with enhanced chemiluminescence (ECL) Western blotting detection reagents (Amersham Pharmacia Biotech, Amersham, UK).

Statistical Analysis

Frequencies were tabulated for categorical variables. Changes in continuous variables not normally distributed

### Table 1 Clinical characteristics and demographics of the study patients

|                | Glenn (n = 17) | Fontan (n = 13) | Control (n = 8) |
|----------------|---------------|-----------------|-----------------|
| Gender: M:F (%)| 10:7 (59)     | 8:5 (62)        | 6:2 (75)        |
| Age (median, IQR) | 5 months (4, 11) | 5 years (4, 6) | 0.3 months (0.3, 3) |
| Lesion (n)     | DORV (3)      | DORV (5)        | AVSD (3)        |
|                | d-TGA (3)     | HLHS (2)        | d-TGA (3)       |
|                | Heterotaxy (3) | DILV (2)       | TOF (2)         |
|                | HLHS (2)      | Other (4)       |                 |

IQR interquartile range, DORV double-outlet right ventricle, AVSD atroventricular septal defect, d-TGA d-transposition of the great arteries, HLHS hypoplastic left heart syndrome, DILV double-inlet left ventricle, TOF tetralogy of Fallot.
within groups were compared using the paired Wilcoxon signed-rank test. Differences in continuous variables between two groups not normally distributed were compared with the Wilcoxon rank-sum test.

**Results**

All the groups had a preponderance of males (Table 1). The age ranges were typical for the stage of palliation, whereas the control group undergoing biventricular repair was significantly younger. The double-outlet right ventricle (DORV) was the predominant lesion in the palliated groups, whereas the lesions in the control group were atrioventricular septal defect (AVSD), d-transposition of the great arteries (d-TGA), and tetralogy of Fallot (TOF).

In the patients undergoing Glenn, endostatin levels decreased postoperatively compared with preoperative levels (4.42 ng/ml; 95 % confidence interval [CI], 4.12–4.70 vs 3.34 ng/ml; 95 % CI, 3.21–3.69 ng/ml; *p* < 0.0001) (Fig. 1). Conversely, in the patients undergoing modified Fontan, pre- and postoperative endostatin levels did not differ (*p* = 0.3).

The patients in the control group undergoing biventricular repair showed a trend toward increasing endostatin levels after surgery (*p* = 0.07) (Figs. 2, 3). The preoperative endostatin levels in the Glenn group were higher than in the modified Fontan and control groups. In addition, the endostatin levels after bidirectional Glenn continued to decrease at the time of the Fontan (3.45 ± 0.7 ng/ml; 95 % CI, 3.21–3.69 vs 2.8 ± 1.2 ng/ml; 95 % CI, 2.3–3.4 ng/ml; *p* = 0.03).

In the patients undergoing bidirectional Glenn, the long-type collagen XVIII levels, as determined by immunoprecipitation, increased postoperatively compared with preoperative levels (optical density: 74,800 [95 % CI, 438,955–1,934,975] vs 2,148,312 [95 % CI, 862,227–5,158,851] + 200 % [*p* < 0.0001]) (Fig. 4). In the patients undergoing modified Fontan, the long-type collagen XVIII levels also increased postoperatively, although to a lesser extent than in the group undergoing bidirectional Glenn (optical density: 434,232 [95 % CI, 204,743.6–663,721.5] vs 440,236 [95 % CI, 211,719–668,754] + 18 % [*p* < 0.01]) (Fig. 4). In the control group, the pre- and postoperative collagen XVIII levels did not differ.
the bcl-2 pathway, and inhibit endothelial cell migrations
inhibition of the VEGFR2 receptor, induce apoptosis via
known to inhibit the VEGF pathway via the competitive
Endostatin, the 20-kDa C-terminus of collagen XVIII, is
*
mosis (Fontan,
middle
sor collagen XVIII increases within 24 h after bidirectional
collagen XVIII. Endostatin decreases, whereas its precur-

Discussion
Since the discovery of endostatin in 1997, its anti-angiogenic properties have been used to treat many types of solid
tumors in cancer patients with varying success [10].
Endostatin, the 20-kDa C-terminus of collagen XVIII, is
known to inhibit the VEGF pathway via the competitive
inhibition of the VEGFR2 receptor, induce apoptosis via
the bcl-2 pathway, and inhibit endothelial cell migrations
via blockade of basic fibroblast growth factor (bFGF) [3, 8,
9, 14, 16]. Its precursor, collagen XVIII, exists both as a
component of the basement membrane and as a circulating
plasma protein. It exists in short, intermediate, and long
isoforms. The short isoform is ubiquitously present in the
basement membrane of various tissues, whereas the long
type seems specific to hepatocytes and liver sinusoids [18].
The biologic roles of collagen XVIII are largely
unknown, but deficiencies have been linked to autosomal-
recessive Knobloch disease, which includes abnormalities
in the vascularization of the retina and encephaloceole
formation [12]. To date, the pathophysiology of long-type
collagen XVIII deficiency has not been described in vivo.
Our data demonstrate significant perioperative changes
in both endostatin and the hepatocyte-specific long-type
collagen XVIII. Endostatin decreases, whereas its precur-
sor collagen XVIII increases within 24 h after bidirectional
Glenn. These findings suggest that the decrease in endo-
statin is not caused by the decreased hepatic production of
its precursor but rather by a potential perturbation in its
cleavage, such as first-pass metabolism by the lungs. The
mechanism for these novel changes is unknown but war-
rants further investigation.

First-pass metabolism by the lung has been described in
other enzymatic processes, including clearance of natri-
uretic peptides and angiotensin-converting enzyme (ACE).
The influence of hepatic venous drainage on pulmonary
metabolism in humans is unclear. However, in an ovine
experimental model of the classic Glenn procedure (i.e.,
anastomosis of the superior vena cava to one divided pul-
monary artery), PAVMs developed reliably on the ipsilateral
side within 8 weeks. The development of these PAVMs was
associated with a decrease in ACE activity and expression
over the first 4 weeks before a subsequent return to baseline
at the end of 8 weeks [11]. These experimental data provide
a framework in which to investigate how the liver may
influence pulmonary vascular metabolism.

Endostatin is released in all isoforms of collagen XVIII
by at least two known pathways. Matrix metalloproteinase
and elastase can release endostatin in a two-step process
[4, 6, 26]. In addition, cleavage of endostatin can occur in a
single step by cathepsin L [4, 25]. Regulation of these
enzymes and the conditions in which they are active or
become inactivated are largely unknown. The data in the
literature are conflicting as to whether hypoxia increases or
decreases endostatin in different animal models [15, 25].
The data suggest, however, that oxygen tension may
influence the enzymatic release of endostatin. Interestingly,
both the basement membrane form, the short isoform, and
the circulating or long isoform release endostatin via the
same enzymatic pathway. This suggests that endostatin
may play a role in both local and systemic inhibition of
angiogenesis [26].

The circulating endostatin levels in patients undergoing
the Glenn procedure for palliation of single-ventricle heart
disease decrease postoperatively. This is associated with an
increase in its precursor, collagen XVII.

Whether these changes represent the fact that endostatin
may normally undergo first-pass metabolism in the lungs,
which then becomes disrupted after Glenn, is unknown but
warrants investigation. We suggest that the decrease in
endostatin, an inhibitor of angiogenesis, may contribute to
the development of clinically important PAVMs. However,
important limitations of this study include its retrospective
design, precluding our ability to correlate the incidence of
PAVM with the change in endostatin levels. In addition, the
amount of plasma available was limited, which prevented
the analyses of collagen XVIII in all patients and other
hepatic regulators of angiogenesis. Therefore, confirmatory
studies of these initial provocative findings are needed.
In addition, a prospective longitudinal study to assess the role of endostatin derived from hepatic-specific collagen XVIII in the pathogenesis of PAVM is warranted and may result in important prevention or treatment strategies to limit cyanosis and promote the longevity of the bidirectional Glenn as a palliative procedure. This would have importance not only in the management of patients with congenital heart disease unsuitable for biventricular repair or further palliation with a modified Fontan operation but also for patients with hepatopulmonary syndrome awaiting a liver transplant.

Acknowledgments This research was supported in part by the UCSF-CTSI Grant UL1 RR024131 from the National Institutes of Health and National Center for Research Resources and HL61284 (to JRF) from the National Institutes of Health.

Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

References

1. Bargeron LM Jr et al (1972) Late deterioration of patients after superior vena cava to right pulmonary artery anastomosis. Am J Cardiol 30:211–216
2. Clement B et al (1999) Homeostatic control of angiogenesis: a newly identified function of the liver? Hepatology 29:621–623
3. Dhanabal M et al (1999) Endostatin induces endothelial cell apoptosis. J Biol Chem 274:11721–11726
4. Felbor U et al (2000) Secreted cathepsin L generates endostatin from collagen XVIII. EMBO J 19:1187–1194
5. Ferrara N et al (1991) The vascular endothelial growth factor family of polypeptides. J Cell Biochem 47:211–218
6. Ferreras M et al (2000) Generation and degradation of human endostatin proteins by various proteinases. FEBS Lett 486:247–251
7. Freedom RM, Yoo SJ, Perrin D (2004) The biological “scrabble” of pulmonary arteriovenous malformations: considerations in the setting of cavopulmonary surgery. Cardiol Young 14:417–437
8. Hanai J et al (2002) Endostatin is a potential inhibitor of Wnt signaling. J Cell Biol 158:529–539
9. Hanai J et al (2002) Endostatin causes G1 arrest of endothelial cells through inhibition of cyclin D1. J Biol Chem 277:16464–16469
10. Herbst RS et al (2002) Phase I study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 20:3792–3803
11. Malhotra SP et al (2001) Superior cavopulmonary anastomosis suppresses the activity and expression of pulmonary angiotensin-converting enzyme. J Thorac Cardiovasc Surg 122:464–469
12. Marneros AG, Olsen BR (2005) Physiological role of collagen XVIII and endostatin. FASEB J 19:716–728
13. Musso O et al (2001) Tumor hepatocytes and basement membrane-producing cells specifically express two different forms of the endostatin precursor, collagen XVIII, in human liver cancers. Hepatology 33:868–876
14. O’Reilly MS et al (1997) Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88:277–285
15. Paddenberg R et al (2006) Hypoxia-induced increase of endostatin in murine aorta and lung. Histochem Cell Biol 125:497–508
16. Ramchandran R et al (2002) Cellular actions and signaling by endostatin. Crit Rev Eukaryot Gene Expr 12:175–191
17. Saarela J et al (1998) Complete primary structure of two variant forms of human type XVIII collagen and tissue-specific differences in the expression of the corresponding transcripts. Matrix Biol 16:319–328
18. Saarela J et al (1998) The short and long forms of type XVIII collagen show clear tissue specificities in their expression and location in basement membrane zones in humans. Am J Pathol 153:611–626
19. Srivastava D et al (1995) Hepatic venous blood and the development of pulmonary arteriovenous malformations in congenital heart disease. Circulation 92:1217–1222
20. Starnes SL et al (2000) Pulmonary microvessel density is a marker of angiogenesis in children after cavopulmonary anastomosis. J Thorac Cardiovasc Surg 120:902–907
21. Starnes SL et al (2000) Vascular endothelial growth factor and basic fibroblast growth factor in children with cyanotic congenital heart disease. J Thorac Cardiovasc Surg 119:534–539
22. Starnes SL et al (2001) Angiogenic proteins in the lungs of children after cavopulmonary anastomosis. J Thorac Cardiovasc Surg 122:518–523
23. Tang L et al (2007) Modulation of pulmonary endothelial endothelin B receptor expression and signaling: implications for experimental hepatopulmonary syndrome. Am J Physiol Lung Cell Mol Physiol 292:L1467–L1472
24. Vettukattil JJ et al (2000) Intrapulmonary arteriovenous shunting may be a universal phenomenon in patients with the superior cavopulmonary anastomosis: a radionuclide study. Heart 83:425–428
25. Wu P et al (2001) Hypoxia downregulates endostatin production by human microvascular endothelial cells and pericytes. Biochem Biophys Res Commun 288:1149–1154
26. Zatterstrom UK et al (2000) Collagen XVIII/endostatin structure and functional role in angiogenesis. Cell Struct Funct 25:97–101